Qilu Pharmaceutical Co., Ltd.

This study tests whether adding the experimental drug QLS31905 to standard chemotherapy helps people with a specific type of advanced pancreatic cancer live longer. About 602 adults whose tumors have a protein called CLDN18.2 will receive either the drug combo or a placebo plus c…

This study tests a new drug called QLC5508 against standard chemotherapy for people with advanced esophageal cancer that has worsened after prior treatments. About 466 adults will be randomly assigned to receive either QLC5508 or a chemotherapy chosen by their doctor. The main go…

This early-stage trial tests a new drug called QLS-1304 in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants will receive the drug alon…

This study tests a drug called QL0911 for cancer patients whose platelet levels drop too low due to chemotherapy. Low platelets can delay treatment or require dose changes. The trial will see if QL0911 safely raises platelet counts so patients can complete their chemo on schedule…

This study tests a new drug called QLC5508, given together with other anti-cancer medicines, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 444 adul…

This study tests a new drug called ESG401 against standard chemotherapy as a first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery. About 504 participants will be randomly assigned to receive either ESG401 or a chemotherapy chose…

This study tests a new drug called QL1706 given before surgery for people with a specific type of colon cancer (MSI-H/dMMR) that has not spread too far. About 363 participants will either get QL1706 or standard care. The goal is to see if the drug can completely eliminate the tum…

This early-stage study tests a new drug called QLS2309 in people with CD70-positive blood cancers that have returned or not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 186 adults will take …

This study tests a new drug called QLS32015 combined with other cancer medicines in 160 people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if these combinations can shrink tumors or make cancer undetectable. Participants will …

This study tests two experimental drugs, QLP2117 and QL2107, together in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About 149 participants will receive the drugs…

This study tests a new drug called QLS32015 against two standard treatments (pomalidomide with dexamethasone, or selinexor with dexamethasone) in 228 adults with multiple myeloma that has returned or stopped responding to prior therapy. The main goal is to see if QLS32015 alone c…

This study tests a new drug called QLS1304 combined with hormone therapy for people with advanced ER+/HER2- breast cancer that has stopped responding to previous hormone treatments. The goal is to find the best dose and see if the combination can shrink tumors or slow the disease…

This study tests a new antibiotic combination (meropenem and pralurbactam) against a standard treatment for serious lung infections caught in the hospital or from a breathing machine. About 420 adults aged 18 to 80 will take part. The goal is to see if the new drug works just as …

This study tests whether a daily pill called relugolix can safely reduce heavy menstrual bleeding in women with uterine fibroids. About 120 premenopausal women will receive either relugolix or a placebo for several weeks. The main goal is to see if the drug lowers blood loss to a…

This early-stage study is testing how much of the antibiotic combination meropenem-pralubactam gets into the lungs of 16 healthy adults in China. Participants will receive four doses of the drug, and researchers will measure its levels in blood and lung fluids. The goal is to und…